Protein unc-13 homolog D (UNC13D)

Protein unc-13 homolog D, also known as Munc13-4, is a critical calcium-dependent regulator of vesicle priming and exocytosis, primarily expressed in hematopoietic cells such as natural killer (NK) cells, cytotoxic T lymphocytes (CTLs), and platelets [UniProt]. It plays an essential role in the final stages of cytotoxic granule maturation, facilitating the docking and priming of these granules at the immunological synapse for the release of perforin and granzymes [PubMed: 14566332]. This process is vital for the immune system's ability to eliminate virally infected or malignant cells. Mutations in the UNC13D gene lead to Familial Hemophagocytic Lymphohistiocytosis type 3 (FHL3), a severe and often fatal hyperinflammatory condition characterized by impaired lymphocyte cytotoxicity and excessive cytokine production [NIH]. While no small-molecule drugs currently target UNC13D directly, it is a primary candidate for gene therapy and CRISPR-based corrective strategies aimed at restoring immune function in FHL3 patients. Additionally, its role in platelet dense granule secretion suggests it may be a target for modulating thrombotic responses, though this remains largely experimental. For biotech analysts, UNC13D represents a high-value diagnostic and therapeutic node in the context of primary immunodeficiencies and immune-mediated inflammatory diseases.

Other names

Munc13-4UNC13DFHL3HLH3HPLH3

Restoration of vesicle priming and exocytic function through gene therapy or protein replacement strategies.